Literature review of visual representation of the results of benefit–risk assessments of medicinal products
Pharmacoepidemiology and Drug Safety2015Vol. 25(3), pp. 238–250
Citations Over TimeTop 10% of 2015 papers
Christine E. Hallgreen, Shahrul Mt‐Isa, A Lieftucht, Lawrence D. Phillips, Diana Hughes, Susan Talbot, Alex Asiimwe, Gerald Downey, Georgy Genov, Richard Hermann, Rebecca Noel, Ruth Peters, Alain Micaleff, Ioanna Tzoulaki, Deborah Ashby, On behalf of PROTECT Benefit–Risk group
Abstract
We have arrived at recommendations for the use of visual displays for benefit-risk communication. The recommendation refers to the creation of visuals. We outline four criteria to determine audience-visual compatibility and consider these to be a key task in creating any visual. Next we propose specific visual formats of interest, to be explored further for their ability to address nine different types of benefit-risk analysis information.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)